|

GVHD prophylaxis Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)2

Indications

  • Cancer2
  • Peripheral T-cell Lymphomas1
  • Immune System Diseases1
  • Lymphoproliferative Disorders1
  • HIV1

Bethesda, Maryland2 trials

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

National Institutes of Health Clinical Center

Phase 2
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

National Institutes of Health Clinical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.